India ·
Temasek- and Motilal Oswal-backed Molbio Diagnostics prices a ₹930cr IPO with a ₹740cr secondary tranche
Motilal Oswal’s India Business Excellence Fund III and thirteen other shareholders are trimming stakes in Molbio Diagnostics’ ₹739.7 crore OFS tranche — alongside the founding promoters, who sell the bulk of it — as the diagnostics maker priced its IPO at ₹768–807/share ahead of an August 10–12 offer.
Source: Outlook Money ↗
Frequently asked questions
Is this an original report, or a copy of the source article?
This is original commentary and context written for this site, citing Outlook Money as the source. Read the full original reporting at the source link below.
How current is this information?
This item reflects reporting as of 5 August 2026. Secondary-market situations like this one can change quickly — check the source link for the latest developments.